Status:
UNKNOWN
Investigation of Plaque Instability Using Bevacizumab-800CW and MSOT
Lead Sponsor:
G.M. van Dam
Conditions:
Atherosclerosis
Carotid Stenosis
Eligibility:
All Genders
21+ years
Phase:
NA
Brief Summary
Determining whether we could visualize uptake of the fluorescent tracer Bevacizumab-800CW, targeting VEGF-A in atherosclerotic plaques by using the new imaging technique Multispectral Optoacoustic Tom...
Detailed Description
Rationale: This project consists of the realization followed by the clinical validation of a procedure dedicated to detect vulnerable atherosclerotic plaques patients with a symptomatic carotid stenos...
Eligibility Criteria
Inclusion
- Patients above the age of 21 with an indication to undergo a carotid endarterectomy for suspected symptomatic atherosclerotic plaque based on the presence of a CVA and/or transient ischemic attacks (TIA's), including amourosis fugax.
- Patients with significant and symptomatic carotid stenosis who are scheduled for carotid endarterectomy as decided by the surgeon or the Multi-Disciplinary Carotid Board
Exclusion
- Medical or psychiatric condition that compromises the patient's ability to give informed consent
- Pregnant or lactating women
- Significantrenal(creatinine\>110μmol/L)dysfunction
- History of iodine allergy or anaphylactic reactions to insect bites or medication or previous allergic reaction to bevacizumab
- Presence or history of hyperthyroidism
Key Trial Info
Start Date :
April 10 2019
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
March 1 2020
Estimated Enrollment :
15 Patients enrolled
Trial Details
Trial ID
NCT03757507
Start Date
April 10 2019
End Date
March 1 2020
Last Update
April 12 2019
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.